PK Intravenous Lidocaine Infusion


To determine safe concentration level of lidocaine infusion in children.

Full Title of Study: “Pharmacokinetics of Intravenous Lidocaine Infusion in Children”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Other
    • Masking: None (Open Label)
  • Study Primary Completion Date: September 2015

Detailed Description

This study will address the working hypothesis that intravenous lidocaine may be administered as a bolus followed by an infusion with reliable and safe blood levels of lidocaine. Serial blood draws will be obtained to determine safety of lidocaine doses used in this study by measuring blood levels of lidocaine and its metabolites.


  • Drug: Lidocaine
    • IV lidocaine bolus of 1.5mg/kg over 10 minutes followed by a 1mg/kg/hr IV lidocaine infusion.

Arms, Groups and Cohorts

  • Experimental: Lidocaine
    • IV lidocaine bolus of 1.5mg/kg over 10 minutes followed by a 1mg/kg/hr IV lidocaine infusion.

Clinical Trial Outcome Measures

Primary Measures

  • Safe serum levels of lidocaine infusion (<5 mcg/ml of lidocaine in blood)
    • Time Frame: Samples will be collected until the end of the OR case and up to 24 hours after surgery
    • Blood samples will be obtained at predetermined times after start and finish of lidocaine infusion. Each sample is 1ml. Samples will be obtained at the baseline placement of IV, 0 – 3 minutes after bolus has completed, 9 – 15 minutes after bolus infusion, 4 minutes prior to end or at the end of the continuous infusion, 55 – 65 following the end of infusion, 2 – 7 hours after completion of continuous infusion and 20 – 24 hours after completion of infusion if clinical labs are also necessary.

Secondary Measures

  • Safe metabolite levels (monoethylglycinexylidide (MEGX) and glycinexylidide (GX) with intraoperative IV lidocaine infusions
    • Time Frame: Samples will be collected until the end of the OR case and up to 24 hours after surgery
    • We will monitor monoethylglycinexylidide (MEGX) and glycinexylidide (GX). Blood samples (1ml each) for metabolites will be as follows: baseline with initial placement, 4 minutes after infusion completed, 2 – 7 hours after infusion completion, 20 – 24 hours after infusion completion if clinical labs are being drawn

Participating in This Clinical Trial

Inclusion Criteria

  • male or female children 3-15 years of age – ASA physical status 1-3 – scheduled for colorectal surgery with abdominal incision Exclusion Criteria:

  • ASA physical status > 3 – postoperative intubation planned ahead of surgery – history of chronic use of opioid (use longer than 3 months) – history of hepatic, renal, or cardiac failure – history of significant liver disease including liver failure, acute or chronic hepatitis, hepatomegaly, portal hypertension and elevated liver enzymes – history of organ transplant – BMI > 30 – history of cardiac arrhythmia – history of long QT syndrome – history of allergic reaction to lidocaine or similar agents – history of seizure disorder – patient without PICC or other central access with contraindication to inhalation induction – family history or known patient susceptibility to malignant hyperthermia

Gender Eligibility: All

Minimum Age: 3 Years

Maximum Age: 15 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Children’s Hospital Medical Center, Cincinnati
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Smokey J Clay, MD, Principal Investigator, Children’s Hospital Medical Center, Cincinnati


Kaba A, Laurent SR, Detroz BJ, Sessler DI, Durieux ME, Lamy ML, Joris JL. Intravenous lidocaine infusion facilitates acute rehabilitation after laparoscopic colectomy. Anesthesiology. 2007 Jan;106(1):11-8; discussion 5-6.

Groudine SB, Fisher HA, Kaufman RP Jr, Patel MK, Wilkins LJ, Mehta SA, Lumb PD. Intravenous lidocaine speeds the return of bowel function, decreases postoperative pain, and shortens hospital stay in patients undergoing radical retropubic prostatectomy. Anesth Analg. 1998 Feb;86(2):235-9.

Candiotti KA, Yang Z, Morris R, Yang J, Crescimone NA, Sanchez GC, Bird V, Leveillee R, Rodriguez Y, Liu H, Zhang YD, Bethea JR, Gitlin MC. Polymorphism in the interleukin-1 receptor antagonist gene is associated with serum interleukin-1 receptor antagonist concentrations and postoperative opioid consumption. Anesthesiology. 2011 May;114(5):1162-8. doi: 10.1097/ALN.0b013e318216e9cb.

Yardeni IZ, Beilin B, Mayburd E, Levinson Y, Bessler H. The effect of perioperative intravenous lidocaine on postoperative pain and immune function. Anesth Analg. 2009 Nov;109(5):1464-9. doi: 10.1213/ANE.0b013e3181bab1bd.

Kuo CP, Jao SW, Chen KM, Wong CS, Yeh CC, Sheen MJ, Wu CT. Comparison of the effects of thoracic epidural analgesia and i.v. infusion with lidocaine on cytokine response, postoperative pain and bowel function in patients undergoing colonic surgery. Br J Anaesth. 2006 Nov;97(5):640-6. Epub 2006 Sep 4.

Harvey KP, Adair JD, Isho M, Robinson R. Can intravenous lidocaine decrease postsurgical ileus and shorten hospital stay in elective bowel surgery? A pilot study and literature review. Am J Surg. 2009 Aug;198(2):231-6. doi: 10.1016/j.amjsurg.2008.10.015. Epub 2009 Mar 12. Review.

Bulloch B, Tenenbein M. Validation of 2 pain scales for use in the pediatric emergency department. Pediatrics. 2002 Sep;110(3):e33.

McGrath PA, Seifert CE, Speechley KN, Booth JC, Stitt L, Gibson MC. A new analogue scale for assessing children's pain: an initial validation study. Pain. 1996 Mar;64(3):435-443. doi: 10.1016/0304-3959(95)00171-9.

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.